Company Performance Metrics
- Roy Farfara: Co-Founder
- Diana Ickowicz: Project Manager
DiaGyn is developing a wide range of solutions to unmet needs demanded by clinical practice in the field of women's health. The company focused on harnessing next-generation sequencing technology to generate clinical-grade genetic screening tests for ovarian cancer risk assessment. It also developing products to diagnose endometriosis and
predict ovarian cancer using noninvasive means, including blood, saliva, and pipelle (endometrial biopsy) samples.
DiaGyn’s first product, DiaVar, is a screening test for ovarian cancer in women who suffer from endometriosis. The test will be based on the analysis of endometriosis-derived samples (laparoscopy biopsies together with saliva). DiaVar’s proprietary panel of genes related to gynecological cancers will then identify any genetic biomarkers in the DNA which indicate an increased probability of developing ovarian cancer.
